Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) Director Mark Steven Davis sold 6,100 shares of Myriad Genetics stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $5.62, for a total value of $34,282.00. Following the sale, the director directly owned 100,565 shares in the company, valued at $565,175.30. This trade represents a 5.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Myriad Genetics Stock Down 1.4%
NASDAQ MYGN opened at $5.46 on Friday. Myriad Genetics, Inc. has a 12 month low of $2.74 and a 12 month high of $8.09. The company has a current ratio of 1.98, a quick ratio of 1.77 and a debt-to-equity ratio of 0.45. The stock has a market cap of $524.20 million, a PE ratio of -4.02 and a beta of 1.62. The stock’s 50 day moving average is $4.98 and its 200 day moving average is $4.62.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. The business had revenue of $202.70 million during the quarter, compared to analyst estimates of $191.33 million. Myriad Genetics had a negative net margin of 16.07% and a negative return on equity of 19.87%. Research analysts predict that Myriad Genetics, Inc. will post -1.02 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Myriad Genetics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. UBS Group initiated coverage on shares of Myriad Genetics in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $3.60 price target on the stock. Craig Hallum increased their price objective on shares of Myriad Genetics from $4.00 to $8.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Wells Fargo & Company set a $4.50 price objective on Myriad Genetics in a research report on Tuesday, October 20th. Finally, TD Cowen raised their price objective on Myriad Genetics from $4.50 to $6.75 and gave the company a “hold” rating in a research report on Thursday, November 5th. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $5.98.
Check Out Our Latest Report on MYGN
Institutional Trading of Myriad Genetics
Large investors have recently made changes to their positions in the business. Allworth Financial LP purchased a new position in Myriad Genetics in the second quarter worth about $25,000. Integrated Wealth Concepts LLC bought a new stake in Myriad Genetics during the second quarter worth approximately $54,000. Pinnacle Associates Ltd. purchased a new stake in Myriad Genetics during the third quarter valued at approximately $44,000. Hsbc Holdings PLC purchased a new stake in Myriad Genetics during the second quarter valued at approximately $61,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Myriad Genetics during the second quarter valued at approximately $67,000. 99.02% of the stock is currently owned by institutional investors.
About Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests to help inform healthcare decisions. Its offerings include tests for hereditary cancer risk, tumor biology and prognosis, reproductive health, and how patients may respond to certain medications. Its products include MyRisk, which assesses inherited cancer risk; GeneSight, a pharmacogenomic test intended to help guide psychiatric medication decisions; and Prolaris, which helps assess the aggressiveness of prostate cancer.
Recommended Stories
- Five stocks we like better than Myriad Genetics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
